You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》麦格理升中生制药(01177.HK)评级至「跑赢大市」 疫苗业务收益强劲
阿思达克 05-25 09:52
麦格理发表报告指,中生制药(01177.HK)公布今年首季业绩,来自疫苗业务的盈利非常强劲,估计首季有12亿元人民币利润来自该业务,意味其持股15%及即将公布业绩的科兴生物(SVA.US)首季盈利或达80亿元人民币。

该行表示,莫德纳(MRNA.US)现时新型肺炎疫苗的目标销售为192亿美元,至於辉瑞(PFE.US)目标则为260亿美元,两企於今年首季的毛利率都有约90%,且销售、一般及行政开支为单位数,估计中生制药来自疫苗的盈利亦会陆续有来。

麦格理上调中生制药股份评级,由「中性」升至「跑赢大市」,目标价由8.39元升至10.46元,并调升集团今明两年每股盈利预测分别62%及33%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account